ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank Of Canada in a report issued on Thursday, reports.

Several other equities analysts have also recently issued reports on the stock. Scotiabank restated an “outperform” rating and issued a C$5.00 price target on shares of ProMetic Life Sciences in a research report on Tuesday, August 16th. TD Securities restated a “speculative buy” rating and issued a C$4.50 price target on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Finally, CIBC decreased their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Shares of ProMetic Life Sciences (TSE:PLI) traded down 2.52% during midday trading on Thursday, hitting $3.09. 1,302,903 shares of the company were exchanged. The firm’s market capitalization is $1.87 billion. ProMetic Life Sciences has a one year low of $1.67 and a one year high of $3.62. The firm’s 50 day moving average price is $2.92 and its 200 day moving average price is $3.01.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About ProMetic Life Sciences

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Stock Target Prices

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.